Interleukin-10 response abnormalities in systemic lupus erythematosus

Scandinavian Journal of Immunology

Volumn 46, Issue 4, 1997, Pages 406-412

  Mongan, A E ^a   Ramdahin, S ^a   Warrington, R J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 0030751975     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-140.x     Document Type: Article

References (50)

1. Linker-Israeli M, Deans RJ, Wallace DJ et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 1991;147:117-23.
2. Spronk PE, Borg EJ, Limburg PC et al. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 1992;90:106-10.
3. Al-Janadi M, Al-Balla S, Al-Dalaan A et al. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993;13:58-67.
4. Ogawa N, Itoh M, Goto Y. Abnormal production of B cell growth factor in patients with systemic lupus erythematosus. Clin Exp Immunol 1992;89:26-31.
5. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992;63:10-11.
6. Metsarinne KP, Nordstrom DC, Konttinen YT et al. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 1992;12:93-6.
7. Swaak AJG, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int 1989;8:263-8.
8. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9.
9. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1992;1:111-17.
10. Kitani A, Hara M, Hirose T et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992;88:75-83.
11. Kitani A, Hara M, Hirose T et al. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6, and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol 1989;77:31-6.
12. Pelton BK, Hylton W, Denman AM. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 1992;89:251-4.
13. Moore KW, O'Garra A, de Waal Malefyt R et al. Interleukin-10. Annu Rev Immunol 1993;11:165-90.
14. Llorente L, Richaud-Patin Y, Fior R et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. Arthritis Rheum 1994;37:1647-55.
15. Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995;144:157-93.
16. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40 L. Cell Immunol 1995;161:226-35.
17. Erikstein BK, Smeland EB, Blomhoff HK et al. Independent regulation of 55 kDa and 75 kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol 1991;21:1033-7.
18. Burdin N, Van Kooten C, Galibert L et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995;154:2533-44.
19. Levy Y, Brouet J-C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-8.
20. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91.
21. Ishida H, Muchamuel T, Sakaguchi S et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
22. Becker TM, Lizzio EF, Merchant B et al. Increased multiclonal antibody-forming cell activity in the peripheral blood of patients with SLE. Int Arch Allergy Appl Immunol 1981;66:293-303.
23. Klinman DM, Steinberg AD. Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med 1987;165:1755-60.
24. Block SR, Lockshin MD, Winfield JB et al. Immunologic observations on 9 sets of twins either concordant or disordant for SLE. Arthritis Rheum 1976;19:545-54.
25. Mackworth-Young C, Schwartz RS. Autoantibodies to DNA. CRC Crit Rev Immunol 1989;8:147-73.
26. Sakane T, Murakawa Y, Suzuki N et al. Familial occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosus. Am J Med 1989;86:385-90.
27. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
28. Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501-14.
29. Wang P, Wu P, Siegel MI et al. Interleukin (IL)-10 inhibits nuclear factor (NFκB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-63.
30. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-330.
31. Gawryl MS, Chudwin DS, Langlois PF et al. The terminal complement complex, C5f-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988;31:188-95.
32. Trizio D, Cudkowicz G. Separation of T and B lymphocytes by nylon wool columns: evaluation of efficacy by functional assay in vivo. J Immunol 1974;113:1093-7.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
34. Notman DD, Kurata N, Tan EM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 1975;83:464-9.
35. Hardin JA. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1986;29:457-9.
36. Minota S, Nojima Y, Yamada A et al. Specificity of autoantibodies to histone H1 in SLE: relationship to DNA-binding domains. Autoimmunity 1991;9:13-19.
37. Burlingame RW, Rubin RL, Balderas RS et al. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993;91:1687-92.
38. Mohan C, Adams S, Stanik V et al. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
39. Burlingame RW, Boey ML, Starkebaum G et al. The central role of chromatin in autoimmune response to histone and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
40. van Es JH, Gmelig Meyling FHJ, van de Akker WRM et al. Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. J Exp Med 1991;173:461-70.
41. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992;22:1719-28.
42. Radik MZ, Mackle J, Erikson J et al. Residues that mediate DNA binding of autoimmune antibodies. J Immunol 1993;150:4966-77.
43. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
44. Henkel T, Machleidt T, Alkalay I et al. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 1993;365:182-5.
45. Leonardo MJ, Baltimore D. NF-κB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58:227-9.
46. Shreck R, Meier B, Mannel DN et al. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992;175:1181-94.
47. Oswald IP, Gazzinelli RT, Sher A et al. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992;148:3578-82.
48. Sano H, Imokawa M, Steinberg AD et al. Accumulation of guaninine-cytosine-enriched low mw. DNA fragments in lymphocytes of patients with systemic lupus erythematosus. J Immunol 1983;130:187-90.
49. Compton LJ, Steinberg AD, Sano H. Nuclear DNA degradation in lymphocytes of patients with systemic lupus erythematosus. J Immunol 1984;133:213-16.
50. Amoura Z, Chabre H, Koutouzov S et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-8.